Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1865-3774
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study ; day:29 ; month:9 ; year:2022 ; pages:1-10
International journal of hematology ; (29.9.2022), 1-10

Creator
Fukuhara, Noriko
Maruyama, Dai
Hatake, Kiyohiko
Nagai, Hirokazu
Makita, Shinichi
Kamezaki, Kenjiro
Uchida, Toshiki
Kusumoto, Shigeru
Kuroda, Junya
Iriyama, Chisako
Yanada, Masamitsu
Tsukamoto, Norifumi
Suehiro, Youko
Minami, Hironobu
Garcia-Vargas, Jose
Childs, Barrett H.
Yasuda, Masanobu
Masuda, Shigeo
Tsujino, Toshiaki
Terao, Yui
Tobinai, Kensei
Contributor
SpringerLink (Online service)

DOI
10.1007/s12185-022-03455-0
URN
urn:nbn:de:101:1-2022121709041629600205
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:27 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Fukuhara, Noriko
  • Maruyama, Dai
  • Hatake, Kiyohiko
  • Nagai, Hirokazu
  • Makita, Shinichi
  • Kamezaki, Kenjiro
  • Uchida, Toshiki
  • Kusumoto, Shigeru
  • Kuroda, Junya
  • Iriyama, Chisako
  • Yanada, Masamitsu
  • Tsukamoto, Norifumi
  • Suehiro, Youko
  • Minami, Hironobu
  • Garcia-Vargas, Jose
  • Childs, Barrett H.
  • Yasuda, Masanobu
  • Masuda, Shigeo
  • Tsujino, Toshiaki
  • Terao, Yui
  • Tobinai, Kensei
  • SpringerLink (Online service)

Other Objects (12)

Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant

Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant

Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Relationship of T- and B-cell kinetics to clinical response in patients with relapsed/refractory non-Hodgkin lymphoma treated with blinatumomab

Relationship of T- and B-cell kinetics to clinical response in patients with relapsed/refractory non-Hodgkin lymphoma treated with blinatumomab

Fluorodeoxyglucose-Positron Emission Tomography in Relapsed/Refractory Hodgkin Lymphoma: A Practical Approach

Fluorodeoxyglucose-Positron Emission Tomography in Relapsed/Refractory Hodgkin Lymphoma: A Practical Approach

Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial

Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial

Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia

Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia

Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study

Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study

Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma

High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma

BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience

BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience

Analysis of Relapsed/Refractory Hodgkin Lymphoma Treated with Autologous Transplantation: A Single-Center Experience

Analysis of Relapsed/Refractory Hodgkin Lymphoma Treated with Autologous Transplantation: A Single-Center Experience

Related objects